Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin ± Aspirin in Lynch Syndrome
NCT04379999Phase 1Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Sep 2018
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atorvastatin in colorectal cancer (CRC) (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoints: Proliferation (Ki-67) at 6 weeks, Apoptosis (active caspase 3) at 6 weeks and 1 more. Started Sep 2018; status: completed.
02
Drugs
atorvastatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04379999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379999.